-
x
x
bid
ask
04:01 AM
![](/assets/images/down.png)
![](/assets/images/up.png)
sentiment
day range
52 week range
Prev Close
Open
Low
High
Volume0.00
Avg. Volume0.00
Market Cap0.00
Inst. Own
Beta
Short Ratio
Div & Yield /
EPS
P/E
1yr Target
50day MA
200day MA
CNQ.TO
Canadian Natural Resources Limited
46.20
04:00 PM
-
0.93
1.97%
G.TO
Augusta Gold Corp.
0.68
03:49 PM
+
0.01
1.49%
AAA.AX
BetaShares Australian High Interest Cash ETF
50.14
01:59 AM
+
0.02
0.04%
ACC.NS
ACC Limited
2438.00
03:58 AM
+
89.45
3.81%
600690.SS
Haier Smart Home Co., Ltd.
25.25
03:00 AM
-
0.06
0.24%
0700.HK
Tencent Holdings Limited
373.20
03:43 AM
+
0.40
0.11%
1101.TW
TCC Group Holdings Co., Ltd.
31.55
01:30 AM
-
0.20
0.63%
20MICRONS.NS
20 Microns Limited
322.50
04:00 AM
-
4.70
1.44%
Day Gain | ||
Gain | ||
Market Val | ||
Costs | ||
Cash | ||
Portfolio | ||
Realized | ||
Dividend |
News
...
Novan Enters into Agreement to Sell Substantially All of its Assets, including Berdazimer Gel, 10.3% (SB206), and Files for Chapter 11 Protection | globenewswire.com • |
Novan, Inc. (NOVN) Q1 2023 Earnings Call Transcript | seekingalpha.com • |
Novan to Report First Quarter 2023 Financial Results on May 15, 2023 | globenewswire.com • |
Novan to Report Full Year 2022 Financial Results on March 30, 2023 | globenewswire.com • |
Novan to Present at the Oppenheimer 33rd Annual Healthcare Conference | globenewswire.com • |
Novan to Present at the Virtual Investor 2023 Companies to Watch Event | globenewswire.com • |
Profile
...
Novan, Inc., a medical dermatology company, focuses on developing and commercializing therapeutic products for skin diseases. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2. Novan, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. The company was incorporated in 2006 and is headquartered in Durham, North Carolina.
Earning
...
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2023-08-10 | 2023-06 | -0.09 | N/A | N/A | N/A |
2023-05-15 | 2023-03 | -0.32 | N/A | N/A | N/A |
2023-03-30 | 2022-12 | -0.31 | N/A | N/A | N/A |
2022-11-14 | 2022-09 | -0.39 | N/A | N/A | N/A |
2022-08-11 | 2022-06 | -0.59 | N/A | N/A | N/A |
2022-05-16 | 2022-03 | -0.57 | N/A | N/A | N/A |
Upgrade / Downgrade
...
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-06-01 | Oppenheimer | Downgrade | Outperform | Perform |
2023-05-16 | Oppenheimer | Upgrade | Outperform | Outperform |
2023-03-31 | Cantor Fitzgerald | Upgrade | Overweight | |
2022-08-16 | HC Wainwright & Co. | Upgrade | Buy | |
2022-07-19 | Oppenheimer | Upgrade | Outperform | |
2021-09-24 | HC Wainwright & Co. | Upgrade | Buy |
Insider Holder
...
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2023-06-06 | BIERMAN JAMES L | Director | 40.10K | Conversion of Exercise of derivative security |
2023-06-06 | GAY JOHN M. | Chief Financial Officer | 46.83K | Conversion of Exercise of derivative security |
2023-06-06 | GEER W KENT | Director | 37.68K | Conversion of Exercise of derivative security |
2023-06-06 | KEEGAN ROBERT J | Director | 42.40K | Conversion of Exercise of derivative security |
2019-07-01 | MALIN LIFE SCIENCES HOLDINGS, LTD. | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Sale |
2019-05-28 | MARTIN G KELLY | Chief Executive Officer | 0.00 | Purchase |
Institution Ownership
...
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-03-30 | Armistice Capital, LLC | 2.25M | 1.26M | 8.02% |
2023-03-30 | Vanguard Group, Inc. (The) | 807.99K | 453.85K | 2.88% |
2023-03-30 | Blackrock Inc. | 302.31K | 169.81K | 1.08% |
2023-03-30 | B. Riley Wealth Advisors, Inc. | 187.00K | 105.04K | 0.67% |
2023-03-30 | Geode Capital Management, LLC | 150.45K | 84.51K | 0.54% |
2023-03-30 | Renaissance Technologies, LLC | 85.37K | 47.95K | 0.30% |
Fund Ownership
...
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2022-12-30 | Vanguard Total Stock Market Index Fund | 545.36K | 306.33K | 1.95% |
2022-12-30 | Vanguard Extended Market Index Fund | 210.18K | 118.06K | 0.75% |
2023-02-27 | Fidelity Extended Market Index Fund | 81.81K | 45.95K | 0.29% |
2023-02-27 | iShares Micro Cap ETF | 41.29K | 23.19K | 0.15% |
2023-02-27 | Fidelity Series Total Market Index Fund | 27.73K | 15.58K | 0.10% |
2023-02-27 | Fidelity Total Market Index Fund | 20.46K | 11.49K | 0.07% |
Split
...
Split | Date |
---|---|
1 : 10 | 2021-05-26 |
1 : 10 | 2021-05-25 |
This topic has been deleted. Only users with topic management privileges can see it.
-
Novan, Inc. (NOVN) Q1 2023 Earnings Call Transcript
seekingalpha.com • -
Novan to Report First Quarter 2023 Financial Results on May 15, 2023
globenewswire.com • -
Novan to Report Full Year 2022 Financial Results on March 30, 2023
globenewswire.com • -
Novan to Present at the Oppenheimer 33rd Annual Healthcare Conference
globenewswire.com • -
Novan to Present at the Virtual Investor 2023 Companies to Watch Event
globenewswire.com • -
Novan, Inc. (NOVN) Q3 2022 Earnings Call Transcript
seekingalpha.com • -
Novan to Report Second Quarter 2022 Financial Results on August 11, 2022
globenewswire.com • -
Novan to Report First Quarter 2022 Financial Results on May 16, 2022
globenewswire.com • -
Novan to Report Full Year 2021 Financial Results on February 22, 2022
globenewswire.com • -
Novan Reports Safety Data from B-SIMPLE4 Pivotal Phase 3 Study of SB206
globenewswire.com • -
Novan to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference
globenewswire.com • -
Novan Announces Strategic Priorities and Outlines Key Milestones
globenewswire.com • -
Novan Engages Syneos Health as Commercial Solutions Provider for SB206
globenewswire.com • -
Novan to Present at H.C. Wainwright 23rd Annual Global Investment Conference
globenewswire.com •